Premium
Clinical use of temporary percutaneous left ventricular assist devices
Author(s) -
Froesch Patric,
Martinelli Michele,
Meier Pascal,
Cook Stéphane,
Hullin Roger,
Windecker Stephan,
Mohacsi Paul,
Meier Bernhard
Publication year - 2011
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.22948
Subject(s) - cardiogenic shock , medicine , impella , conventional pci , percutaneous coronary intervention , percutaneous , cardiology , ventricular assist device , shock (circulatory) , ventricular function , retrospective cohort study , surgery , heart failure , myocardial infarction
Background : Temporary percutaneous left ventricular assist devices (TPLVAD) can be inserted and removed in awake patients. They substitute left ventricular function for a period of up to a few weeks and provide an excellent backup and bridge to recovery or decision.Methods : Retrospective analysis of 75 patients who received TPLVAD to treat cardiogenic shock ( n = 49) or to facilitate high‐risk percutaneous coronary intervention (PCI) ( n = 26). Forty‐two patients with cardiogenic shock and 16 patients with high‐risk PCI received a TandemHeart and 7 patients and 10 patients, respectively, received an Impella Recover LP 2.5. Outcome and related complications up to 1 month are reported with reference to device depending function.Results : One‐month survival was 53% in patients with shock and 96% in patients with PCI.Conclusion : TPLVADs can support the failing heart with acceptable risk. Outcome is better in prophylactic use than in patients with cardiogenic shock. © 2011 Wiley‐Liss, Inc.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom